Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.
Individuals with advanced non-small-cell lung cancer continue to derive a long-term survival benefit from second- or later-line treatment with nivolumab versus docetaxel, according to 5-year results from the CheckMate 017 and 057 trials.
Trilaciclib affords myelopreservation in individuals with small-cell lung cancer treated with first-line chemotherapy, without impacting treatment efficacy, research indicates.
Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.
Non-small-cell lung cancer patients with poor performance status or comorbidity experience a similar adverse event rate to those with normal performance status when treated with nivolumab plus ipilimumab, say researchers.
The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.